Results 51 to 60 of about 14,468 (240)

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Psychedelics in the treatment of unipolar and bipolar depression

International Journal of Bipolar Disorders, 2022
This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research.
Oliver G. Bosch, Simon Halm, Erich Seifritz   +2 more
doaj   +1 more source

Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder

Frontiers in Psychiatry, 2023
IntroductionCannabis use disorder (CUD) is prevalent in ~2–5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase.
Angela N. Phan, Garth E. Terry, Garth E. Terry   +2 more
doaj   +1 more source

Breaking Out of One’s Head (& Awakening to the World) [PDF]

, 2019
Herein, I review the shattering moment in my life when I awoke from the dream of self to find being as part of the living world and not in my head, discovering my perspectival center to be literally everywhere.
Nixon, Gregory
core  

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

An Integrated theory of false insights and beliefs under psychedelics

Communications Psychology
Psychedelics are recognised for their potential to re-orient beliefs. We propose a model of how psychedelics can, in some cases, lead to false insights and thus false beliefs. We first review experimental work on laboratory-based false insights and false
H. T. McGovern, H. J. Grimmer, M. K. Doss, B. T. Hutchinson, C. Timmermann, A. Lyon, P. R. Corlett, R. E. Laukkonen   +7 more
doaj   +1 more source

Regulatory Challenges of Integrating Psychedelics into Mental Health Sector

Psychoactives
Psychedelic substances have recently emerged as a promising method for treating mental health conditions, despite a history of stigmatization and restriction in use.
Kerem Kemal Soylemez, Emma Marie de Boo, Joanne Lusher   +2 more
doaj   +1 more source

Psychedelics and Immunomodulation: novel Approaches and Therapeutic Opportunities [PDF]

, 2017
Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular ...
Szabó, Attila
core   +4 more sources

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

Treating addiction with psychedelics - are we waking up?

European Psychiatry, 2021
Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the ...
J. Miranda, M. Barbosa, I. Figueiredo, P. Mota, A. Tarelho   +4 more
doaj   +1 more source